Neogen Chemicals corrects typographical errors in Q2 FY26 standalone and consolidated financial results
Neogen Chemicals corrected minor typographical errors in its Q2 FY26 standalone and consolidated financial results, specifically for DSCR and ISCR, confirming no material impact on financials.
The corrections are for non-material typographical errors in financial ratios and do not affect the underlying financial performance, thus having a low impact on the company or its stock price.
The company explicitly stated that the errors were typographical, not material, and did not impact the financial statements, indicating no significant positive or negative change.
Neogen Chemicals Limited issued a corrigendum on November 11, 2025, to correct typographical errors in Note no. 1 of its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. These corrections, submitted in furtherance to the board meeting outcome on November 8, 2025, relate to additional disclosures under Regulation 52(4) of Listing Regulations. The company clarified that the errors are not material and do not impact the financial statements.
* Standalone Financial Results (Q2 & H1 FY26): * Debt Service Coverage Ratio (DSCR) (Trailing twelve months) corrected to 2.38 (previously stated: 2.11). * Interest Service Coverage Ratio (ISCR) (Trailing twelve months) corrected to 2.51 (previously stated: 3.59). * Consolidated Financial Results (Q2 & H1 FY26): * Debt Service Coverage Ratio (DSCR) for the quarter ended September 30, 2025, corrected to 0.97 (previously stated: 0.75). * Debt Service Coverage Ratio (DSCR) for the half year ended September 30, 2025, corrected to 1.44 (previously stated: 0.99). * Debt Service Coverage Ratio (DSCR) (Trailing twelve months) for both the quarter and half year ended September 30, 2025, corrected to 1.99 (previously stated: 0.77 and 0.74 respectively).
What to do with a filing like this
Neogen Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neogen Chemicals Limited. Read the original for the full detail.